ICORD - Stockholm 2/’05 The EU Experience with Orphan Drugs View of the Biotech Industry Erik Tambuyzer - Genzyme Europe Chair Healthcare Council, EuropaBio.

Slides:



Advertisements
Similar presentations
4th Poverty Reduction Strategies Forum Athens, June 27 th, 2007 Regional Energy market in Southeast Europe: Prospects and challenges for the SEE countries.
Advertisements

Consultative expert working group - proposals Barcelona
EU rare diseases registry for Niemann-Pick Disease type A, B and C Tarekegn Hiwot Consultant in Inherited Metabolic Disorders University Hospital of Birmingham.
Engaging Patients and Other Stakeholders in Clinical Research
The Paediatric Regulation
EU Cross-Border Care Directive from the Primary Care perspective Results of a simulation Rita Baeten Gothenburg, 3 September 2012.
Ageing Well in the Information Society
Policy recommendations for wider implementation of telemedicine Peeter Ross, MD, PhD e-Health expert, Estonian eHealth Foundation, Estonia.
Healthy Life Expectancy and EU Policy
Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.
An introduction to the EU and its legislation. Member States currently 15 –Austria- Ireland –Belgium- Luxembourg –Denmark- Netherlands –Finland- Portugal.
David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
1 Europe André Meijer Universiteit Maastricht Programme director European Public Health.
A Common Immigration Policy for Europe Principles, actions and tools June 2008.
ADAMOS ADAMOU, MEDICAL ONCOLOGIST MEMBER OF THE EUROPEAN PARLIAMENT.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
REGIONAL POLICY EUROPEAN COMMISSION The EU Recovery Plan and the proposal amending the European Regional Development Fund Regulation.
Horizon 2020 The EU Framework Programme for Research and Innovation Health, Demographic Change and Wellbeing Lul Raka, NCP for Horizon 2020 – Health.
London cancer services: Implementing the model of care London Borough of Bromley Health Scrutiny Sub-Committee meeting Tuesday, November 15, 2011.
The Role of Patients in EU Policy Development European Health Forum Gastein October 2003 – Bad Gastein Presented by Erick Savoye Director of the European.
Quality of Healthcare in Europe Royal College of Physicians London Council Chamber 19 January 2009 Robert Madelin Director General for Health and Consumers.
European Commission Preparation of the Innovation Union Flagship Initiative European Commission Presentation to ERAC 11 June 2010.
Dr Peter Arlett European Commission Orphan medicines: DG Enterprise and Industry perspective ICORD February 2005.
Euei1. 2 Facilitation Workshop and Policy Dialogue Maputo April 2005 Enrico Strampelli European Commission DG Development.
Safe and Effective Medicine for Children Daring to be Rare, BIOTECanada Panel 2015 CADTH Symposium Saskatoon, April
A major step towards a Europe for Health Directive on patients’ rights in cross-border healthcare DG SANCO D2 Healthcare Systems.
FP7 - April The European Research Area in the Age of Globalisation Henri Delanghe DG RTD, C4 (Economic and Prospective Analysis Conference on Knowledge.
Europe's work in progress: quality of mHealth Pēteris Zilgalvis, J.D., Head of Unit, Health and Well-Being, DG CONNECT Voka Health Community 29 September.
EU Funding opportunities : Rights, Equality and Citizenship Programme Justice Programme Jose Ortega European Commission DG Justice.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
Eurocarers and EU level policy Eurocarers EGA, 16 November 2010 Christine Marking Advisor to the Eurocarers Executive Committee.
National Plans for Rare Diseases: Bulgarian experience ICORD meeting – February 2009, Roma, Italy Rumen Stefanov.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
EU Infrastructure charging and investment policy Christophe Deblanc DG TREN.
EARIP Stakeholder Workshop Models and healthcare systems: transferability of best practice across Europe Dr. Aurélien PEREZ European Commission Health.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
E u r o p e a n C o m m i s s i o nCommunity Research Global Change and Ecosystems EU environmental research : Part B Policy objectives  Lisbon strategy.
Horizon Scanning: future skills and competences of the health workforce in Europe MATT EDWARDS and JOHN FELLOWS WP6, EU JA on Health Workforce Planning.
A STRONG PATIENTS’ VOICE TO DRIVE BETTER HEALTH IN EUROPE.
EPHA Briefing Paper (Part 2): High Level Reflection Process on Patient Mobility in the EU - summary of final recommendations - December 2003 (See also.
EC actions against the rising threats from Antimicrobial Resistance
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
Networking on social inclusion The role of NGOs in tackling poverty and social exclusion: Aims and achievements of the European Anti Poverty Network Istanbul,
19-20 October 2010 IT Directors’ Group meeting 1 Item 6 of the agenda ISA programme Pascal JACQUES Unit B2 - Methodology/Research Local Informatics Security.
Michael Schmoeltzer Member of ERGEG Gas Working Group GIE Annual Conference, 6/7 May 2009, Groningen ACER & ENTSOG and their interaction.
1 Brussels 16 January What is HOPE? HOPE is an excellent example of the diversity of European healthcare system What is HOPE? HOPE is an excellent.
1 ECPC PAPER ON BLADDER CANCER FRANCESCO DE LORENZO Brussels, 20 April 2016.
Bulgarian National Hepatitis Plan and Compassionate Use Regulations Dr. Stanimir Hasardzhiev Executive Director, ELPA Chairperson, Hepasist REPUBLIC OF.
National Information Day Greece 23 July 2015 Funding priorities under the work plan 2015.
Week 12. Lecture 2. Health Law & the EU Cross-border healthcare: patients’ rights.
EU context (networks & initiatives) and expectations EU context (networks & initiatives) and expectations Michel Viaud and/or Ingrid Weiss EPIA, Brussels,
A look into current and future trends in national policies for eHealth and Innovation in the WHO European Region Clayton Hamilton, eHealth and Innovation.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
Direct-to-Consumer Genetic Testing: Outputs from the EASAC-FEAM Working Group Martina Cornel VU University Medical Center, Amsterdam.
Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
Health and Food Safety Overview - Work Programme 2016 National Info day Athens, 21 April 2016.
European Patients’ Academy on Therapeutic Innovation – The project is receiving support from the.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
A capacity building programme for patient representatives
MEP Interest Group on Brain, Mind and Pain
Health Technology Assessment
Community Pharmacy: Sharing Our Vision
EU Reference Centres for Animal Welfare
EU centralised programmes for Social Farming
EUnetHTA Assembly May 2018.
Presentation transcript:

ICORD - Stockholm 2/’05 The EU Experience with Orphan Drugs View of the Biotech Industry Erik Tambuyzer - Genzyme Europe Chair Healthcare Council, EuropaBio

What is EuropaBio ? u EuropaBio is the European Biotechnology Industry Association representing 40 globally operating biotechnology companies and 24 national associations, representing more than 1500 small and medium-sized companies. u It aims to be a promoting force for biotechnology and makes proposals to industry, politicians, regulators, non government organisations, and the public at large. u EuropaBio’s Core Ethical Values (CEV) are available since 1998 in 11 languages. For information, see

The EU Orphan Medicinal Products Regulation (141/2000) Its purpose is to provide: Effective therapies for patients with rare diseases, and Incentives to industry to develop these therapies. The core of the OMP Regulation consists of non-economic societal values representing the desire for provide equitable access to therapies independent of the rarity of the disease

Example of effective treatment (Gaucher’s disease)

Current Situation Analysis The Regulation has had a successful start: 254 designations since 4/2000 compared to nearly no EU-developed products before Up to now, 20 Orphan Medicinal Products have been granted EU Marketing Authorisation It is too soon to judge results - but the outlook is promising - we should all support this Regulation The Regulation does not concentrate on research programs nor on access The Study by Alcimed confirmed that the price for an OMP in the EU is related to rarity of the disease The EU is now EU-25: does it make a difference?

Industry’s conclusions: The Regulation needs full application in a spirit of collaboration with all stakeholders The Regulation should be predictable: policy continuity for trust and progress There is a strong need for a broader EU framework and for more coordination There is a lot to do on the understanding of the Regulation and its implications in the EU Member States

Address issues minimally at country level Work to do on awareness and education regarding rare diseases, including for health professionals/clinicians Regional inequalities in information, education, prevalence, diagnosis, access and reimbursement – need to address at national level or EU level The Regulation needs to be explained, also in the enlargement Member States

EU Research Priorities for Rare Diseases More coordination of research plus link with the OMP Regulation Link with the objectives of the Lisbon treaty (“EU to be leading knowledge-based economy”) – many OMPs are developed by small companies (SME’s) Since 70-80% of rare diseases have a genetic origin, biotechnology will play a major role in developing treatments for them

Accurate and Timely Diagnosis to enable Timely Treatment Rare disease patients are diagnosed late Rarity and heterogeneity of the disease Late diagnosis is often associated with poor prognosis Screening or diagnosis not well-established Individuals cannot always be treated timely by lack of good diagnosis, even if clinically effective medicines are available Diagnostic and population and/or newborn screening services are integral part of good care if therapy exists An EU-wide network of diagnostic centers for rare diseases

ICORD - Stockholm 2/’05 If a therapy prevents clinical symptoms: is it acceptable to wait? Irreversible complications => too late to treat? A Sense Of Urgency

Recent Recommendations by STRATA (EU Expert Group*) Medically relevant genetic testing to be considered an integral part of health services provision National healthcare systems to ensure that genetic testing will be accessible equitably to all who need it EC to take measures to facilitate availability of genetic testing for rare diseases as well as for more common diseases EU-wide network for diagnostic testing of rare genetic diseases to be created and financially supported as a matter of urgency EU-level incentive system for the systematic development of genetic tests for rare diseases to be created and financially supported For rare but serious diseases with treatment available: Member States should introduce universal neonatal screening as a priority * STRATA group, May Published by European Commission’s DG Research “Ethical, legal, social issues of genetic testing: research, development and clinical applications”

Pompe disease is a rare and fatal lysosomal storage disorder (LSD) with an estimated prevalence of 5,000 – 10,000 patients in the developed world. Children with the infantile form die at months and need treatment before they are 6 mo’s old to be effective. Adult Childhood and Juvenile Infantile DelayedOnset Need for early diagnosis, e.g. in Pompe Disease

Infantile-Onset Pompe Disease: Head Lag

Compassionate Use: a shared Responsibility Needs definition A shared responsibility between the clinician, the developer of the product and the authorities France (ATU system), Italy and Belgium (Solidarity Fund) fund the supply of Orphan Medicines to patients in high need before regulatory approval or before reimbursement. Sustainable, appropriate systems in other European Member States? Many OMPs are developed by SME’s May create dilemma’s when product is scarse

Predictable Climate and Policy Continuity for OMPs Interpretation of the Regulation should not change over time: foster R&D by a predictable regulatory climate Avoid confusion about the most important incentive – the market exclusivity: Should not be weakened, US provides other incentives and industry will publish survey on impact Does not create monopolies or block innovation Does not lead to higher prices – see Alcimed study: the disease rarity does

Timely and Equitable Access and Definition of Value of Innovation Timely and equitable patient access to orphan medicines in the EU is not guaranteed Of the first 10 Orphan Medicinal Products approved in Europe, only 50% are available in the 15 “old EU” Member States (EURORDIS survey) Cost-effectiveness for rare disease therapies: can existing health economic methods be used? (what about ultra-orphan medicines defined by NICE as having prevalence <1/50,000)? Determination of value of a new OMP at launch?

Value: Joint mobility in MPS-I beforeafter 26 weeks of ERT E. Kakkis NEJM 2001

Incentives for OMPs Tax incentives are impossible through the EU Regulation. EU Member States need to improve its competitiveness with the US Orphan Drug Act Few European countries have provided OMP incentives so far, in spite of the priority given to the field of rare diseases at EU level More awareness and explanation are incentives Earlier availability and access for OMPs are most important incentives both for patients and for industry Proposal for 2 years extra market exclusivity for paediatric medicines for rare diseases is right step if it is no obligation.

Clinical trials in rare diseases The Clinical Trial Directive is making clinical trials for rare diseases more complex Review of the level of cost implications for post-marketing commitments for OMPs Post-approval commitments and additional trial requests should be ethical and feasible under national rules Avoid bureaucracy for cross-border clinical trials and for small protocol changes for orphan medicines Careful with paediatric data requests

Conclusions Good start – congratulations to all involved More work ahead, especially on awareness, diagnosis and access (Industry will present its White Paper soon) Products to treat rare diseases need EU or at least national level Policy continuity needed to guarantee further progress Partnerships involving patients, researchers & clinicians, authorities and industry are the way forward in this field

ICORD - Stockholm 2/’05 Thank you for your attention! Questions?